Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction
Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to…
Ipsen announces that Beech Tree has obtained an exemption from the obligation to submit a public tender offer
April 03, 2026 01:00 ET | Source: Ipsen Pharma PARIS, FRANCE, 3…
Ipsen announces the availability of its 2025 Universal Registration Document
Ipsen announces the availability of its 2025 Universal Registration Document PARIS, FRANCE,…
Ipsen – January 2026 – Monthly information relative to the total number of voting rights and shares composing the share capital
Monthly information relative to the total number of voting rights and shares…
New data reinforces Ipsens commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS
14 abstracts will be presented across a range of neurological conditions including…
Ipsen – November 2025 – Monthly information relative to the total number of voting rights and shares composing the share capital
Monthly information relative to the total number of voting rights and shares composing…
Ipsen provides update on legacy of Henri Beaufour
PARIS, FRANCE, 5 December 2025, Ipsen (Euronext: IPN; ADR: IPSEY) has been informed…
Ipsen – September 2025 – Monthly information relative to the total number of voting rights and shares composing the share capital
Monthly information relative to the total number of voting rights and shares…
IPSEN – Buy-back programme – Art 5 of MAR – Week 36 – 2025
Aggregated presentation by day and by marketStatement of transactions in own shares…
IPSEN – Buy-back programme – Art 5 of MAR – Week 33 – 2025
Aggregated presentation by day and by marketStatement of transactions in own shares…
